ALSO NOTED: Medicure raises $40M; FDA wants more data on Creon; Genta launches Phase III; and much more...

> Medicure has struck two deals to raise $40 million. Release

> The FDA has issued an approvable letter for Solvay's Creon--a pancreatic enzyme for the treatment of pancreatic exocrine insufficiency--but wants more data before it can give the therapy its full blessing. Release

> Genta announced that the first patients have been enrolled in the company's confirmatory Phase III trial of Genasense Injection in advanced melanoma. Release

> Sirtris Pharmaceuticals has initiated a Phase IIa clinical trial to evaluate its SRT501 product candidate in patients with Type 2 Diabetes whose glucose levels are not adequately controlled by their metformin treatment. Release 

> Perrigo has launched a patent dispute with Adams Respiratory. Release

> A new research report concludes that Gilead may be stealing GlaxoSmithKline's "Best anti-HIV drug maker" crown, thanks to Gilead's drug-combo pill Atripla. Release

> Merck may have had a near-death experience, but now it's found a survival strategy: fight every Vioxx case as if it were the only one. FiercePharma

> Pharma observers just won't stop matchmaking. A Credit Suisse analyst wants Pfizer to buy out Wyeth, noting that Wyeth stock has plummeted 19 percent since July 23 on a string of bad news. But Wyeth's pipeline is promising, and its biotech drugs are strong--so it's a bargain. FiercePharma 

And Finally... The race is on to produce synthetic life. FierceBioResearcher